small molecule

MYCAPSSA

OCTREOTIDE ACETATE

Loss of exclusivityDecember 2040latest FDA-listed patent expiry
CompanyCHIESI FARMACEUTICI SPA

Drug detail

Brand nameMYCAPSSA
Active ingredientOCTREOTIDE ACETATE
StrengthEQ 20MG BASE
Dosage formCAPSULE, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2020
Marketing statusRX

Listed patents

PatentExpiresType
11141457December 2040use U-3232
11890316December 2040use U-3232
12246054February 2036use U-2857
10695397February 2036use U-2857
10238709February 2036use U-2857
11510963February 2036use U-2857
11052126February 2036use U-2857
11857595February 2036use U-3784
11338011February 2036use U-2857
12251418February 2036use U-2857
8535695September 2029use U-2857
11986529September 2029use U-2857
11969471September 2029product
8329198September 2029product
9265812September 2029product
9566246September 2029product

Regulatory exclusivity

CodeExpires
ODE-474June 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MYCAPSSA patent cliff — loss of exclusivity December 2040 | CliffBio